PR Newswire - Ractigen Therapeutics Announces U.S. FDA IND Clear...
RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's ...
Read More


ภาษาไทย
English